I
Indigo Diabetes
Develops invisible sensors for people living with diabetes
About Indigo Diabetes
Indigo Diabetes N.V. is a Belgian medical device company developing a continuous multi-metabolite monitoring (CMM) system for people with chronic diseases, with an initial focus on diabetes. Founded in 2016 by Dr. Danaë Delbeke and her team as a spin-off from Ghent University and imec, a leading research center in nanoelectronics, the company is headquartered in Ghent, Belgium, with a US subsidiary, Indigo Medical US Inc., in Boston.
Read full description
The founder and CTO, Danaë Delbeke, has a PhD in Applied Sciences from Ghent University and a background in both photonics engineering and economics. Her work in photonics and a desire to make a tangible impact on quality of life led to the creation of Indigo. Delbeke is a serial entrepreneur, having founded or co-founded seven high-tech photonics companies. The management team includes CEO Peter J. Devlin, who has extensive experience at companies like Abbott Laboratories and Insulet Corporation.
The company's core product is a subcutaneously implanted CMM sensor designed to be invisible after insertion. This sensor utilizes proprietary nanophotonics technology, effectively a miniaturized spectrometer-on-a-chip, to measure the absorption of light in interstitial fluid. This allows for the simultaneous, continuous, and real-time monitoring of multiple metabolites like glucose, ketones, and lactate without using enzymes or fluorophores. The data is transmitted wirelessly via Bluetooth to a mobile app, providing users and their caregivers with actionable insights to manage their condition. The implantable sensor is designed to have a lifespan of up to two years.
Indigo's business model centers on the development and eventual commercialization of this medical device for the chronic disease management market. The company has raised significant capital to fund its research, development, and clinical trials. In 2016, it secured a €7 million Series A round. This was followed by a €38 million Series B round in 2020, led by Fund+, to prepare for and initiate clinical studies in Europe and the US. The company has successfully completed its first-in-human (GLOW) and longer-term stability (SHINE) clinical trials and has received ISO 13485:2016 certification for its quality management system. While the initial market is diabetes management, Indigo plans to explore applications for its CMM sensor in other chronic conditions such as kidney disease, oncology, and cardiovascular disease. Keywords: continuous metabolite monitoring, implantable sensor, nanophotonics, diabetes management, medical devices, glucose monitoring, ketone monitoring, silicon photonics, medtech, chronic disease
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Ghent, Belgium
- Employees
- 34
- Open positions
- 1
- Dealroom signal
- 74.6/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Personal Health, Diabetes, Remote Monitoring, Spinout
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning, Computer Vision, IoT InternetOfThings
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Indigo Diabetes.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2020 | $42M | $167M | Ackermans & van Haaren · imec.xpand · FundPlus · Capricorn Partners | ↗ |
| GRANT✓Other financing | Feb 2018 | $0 | — | European Innovation Council | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Indigo Diabetes is 750 monthly website visits, down 5.1% over the last three months. Indigo Diabetes's team declined 2.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A9 investors entered at this stage
PMV
Thuja Capital- FIFidimec
Capricorn Partners
SoFi
Qbic Fund
FundPlus
Ackermans & van Haaren
imec.xpand
Other known investors3 additional known investors
Ghent University
imec
Quest for Growth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Indigo Diabetes on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Indigo Diabetes’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







